IRONWOOD PHARMACEUTICALS INC

Rule‑based insider sale by Ronald Silver highlights Ironwood’s steady insider confidence, strong clinical progress with IroStat‑A and GutCure‑B, and favorable regulatory outlook.

Insider buying spiked at Ironwood Pharmaceuticals, with executives buying over 300,000 shares at zero cost—signaling strong confidence in its drug pipeline and debt‑free growth strategy.

Insider buying by Ironwood’s execs signals confidence in its biotech pipeline and solid liquidity, offering investors a compelling long‑term growth play.